A detailed history of Lindbrook Capital, LLC transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 171 shares of HRMY stock, worth $5,824. This represents 0.0% of its overall portfolio holdings.

Number of Shares
171
Previous 180 5.0%
Holding current value
$5,824
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$30.0 - $39.95 $270 - $359
-9 Reduced 5.0%
171 $6,000
Q2 2024

Jul 31, 2024

BUY
$28.81 - $33.01 $1,382 - $1,584
48 Added 36.36%
180 $5,000
Q4 2023

Jan 31, 2024

BUY
$19.2 - $33.78 $2,534 - $4,458
132 New
132 $4,000
Q2 2023

Jul 28, 2023

BUY
$30.5 - $37.4 $335 - $411
11 New
11 $0
Q4 2022

Jan 24, 2023

SELL
$45.4 - $60.91 $2,769 - $3,715
-61 Reduced 44.53%
76 $0
Q3 2022

Nov 10, 2022

BUY
$42.06 - $55.45 $5,551 - $7,319
132 Added 2640.0%
137 $6,000
Q2 2022

Aug 01, 2022

BUY
$33.54 - $52.15 $167 - $260
5 New
5 $0

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.02B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.